A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer
Advanced Science · 2026
DOI: 10.1002/advs.75933 ↗At a glance
Multizentrische Studie in Advanced Science, 2026. Written by Yanglan Xu and 10 co-authors. Institution: Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Immunotherapy, Lung Neoplasms, Neoadjuvant Therapy. 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Excellent Young Talents Project of Shanghai Public Health Three-year (2023-2025) Action Plan.
Abstract (original language)
Predicting pathological complete response (pCR) to neoadjuvant immunochemotherapy in non‐small cell lung cancer (NSCLC) is clinically important yet remains challenging. Here, we introduce a foundation model‐derived computed tomography (CT) imaging biomarker established from a multi‐center cohort of 702 patients. Specifically, we developed and validated a non‐invasive baseline CT‐based model for risk stratification of pathological response. To address scanner and protocol heterogeneity, we first built a 3D Vision Mamba‐based CT super‐resolution model trained on 2494 cases for image standardization. We then fine‐tuned a lung cancer‐specific CT foundation model from a pretrained 3D model (VoCo) using 6643 chest CT scans. Finally, we constructed a multi‐task Swin Transformer that jointly performs risk stratification and segments tumors to generate the imaging biomarker. Across five centers, the model achieved consistently strong generalization (AUC: 0.75–0.87) for pCR prediction. Genomic analysis revealed that the biomarker was independent of tumor mutational burden but significantly associated with TP53 mutations, suggesting an association with a radiogenomic phenotype related to this alteration. Together, these results demonstrate a generalizable and biologically meaningful foundation model‐based biomarker for non‐invasive risk stratification of pathological response in NSCLC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Radiology, Shanghai Pulmonary Hospital, Shanghai, China.
- Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Institute of Medical Imaging, Shanghai, China.
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Excellent Young Talents Project of Shanghai Public Health Three-year (2023-2025) Action Plan
- Science Foundation of Peking University Cancer Hospital
- Natural Science Foundation of Shanghai Municipality
Cite
APA
Xu, Y., Zhou, S., Peng, Q., Bao, X., Ye, X., Er, A. G., Tong, T., Rusu, M., Gu, Y., Chen, M., & Gong, J. (2026). A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.75933
Vancouver
Xu Y, Zhou S, Peng Q, Bao X, Ye X, Er AG, et al. A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer. Advanced Science. 2026. doi:10.1002/advs.75933
BibTeX
@article{Xu2026,
author = {Xu, Yanglan and Zhou, Shuchang and Peng, Qin and Bao, Xiao and Ye, Xiaodan and Er, Ahmet Görkem and Tong, Tong and Rusu, Mirabela and Gu, Yajia and Chen, Mailin and Gong, Jing},
title = {A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75933}
}
EUVIMED